Analysts on Wall Street project that Eli Lilly (LLY Quick QuoteLLY - Free Report) will announce quarterly loss of $0.11 per share in its forthcoming report, representing a decline of 105.6% year over year. Revenues are projected to reach $8.88 billion, increasing 27.9% from the same quarter last year.

The consensus EPS estimate for the quarter has been revised 2% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.

Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.

While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.

That said, let's delve into the average estimates of some Lilly metrics that Wall Street analysts commonly model and monitor.

The consensus among analysts is that 'Net Sales- Olumiant/Baricitinib (LY3009104)/JAK1/JAK2 Inhibitor- Total' will reach $228.14 million. The estimate indicates a change of +24.7% from the prior-year quarter.

Based on the collective assessment of analysts, 'Net Sales- Erbitux [$M]' should arrive at $151.75 million. The estimate indicates a year-over-year change of +4.7%.

Analysts predict that the 'Net Sales- Alimta [$M]' will reach $52.32 million. The estimate indicates a change of -56.2% from the prior-year quarter.

It is projected by analysts that the 'Net Sales- Oncology [$M]' will reach $1.70 billion. The estimate indicates a year-over-year change of +31.5%.

The consensus estimate for 'Net Sales- US-Alimta [$M]' stands at $17.14 million. The estimate suggests a change of -73.5% year over year.

Analysts' assessment points toward 'Net Sales- International-Humalog [$M]' reaching $187.13 million. The estimate indicates a year-over-year change of -5.9%.

The collective assessment of analysts points to an estimated 'Net Sales- International-Forteo [$M]' of $49.76 million. The estimate points to a change of -22.7% from the year-ago quarter.

Analysts expect 'Net Sales- International-Alimta [$M]' to come in at $35.15 million. The estimate suggests a change of -35.9% year over year.

According to the collective judgment of analysts, 'Net Sales- US-Humulin [$M]' should come in at $153.41 million. The estimate points to a change of -9.5% from the year-ago quarter.

The combined assessment of analysts suggests that 'Net Sales- US-Humalog [$M]' will likely reach $248.10 million. The estimate points to a change of 0% from the year-ago quarter.

Analysts forecast 'Net Sales- US-Forteo [$M]' to reach $82.92 million. The estimate indicates a change of -26.4% from the prior-year quarter.

The average prediction of analysts places 'Geographic Revenue- United States' at $5.99 billion. The estimate indicates a change of +35.5% from the prior-year quarter.

View all Key Company Metrics for Lilly here>>>

Lilly shares have witnessed a change of +5.5% in the past month, in contrast to the Zacks S&P 500 composite's -2.2% move. With a Zacks Rank #3 (Hold), LLY is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>